Eflucimibe is an ACAT inhibitor. Eflucimibe regulates endogenous hypercholesterolemia in a synergistic manner in New Zealand rabbits fed a casein-enriched diet. In vivo, orally administered Eflucimibe displayed high potency and efficacy as an antihypercholesterolemic compound in different cholesterol-fed animals (guinea-pig, rat, rabbit).
Eflucimibe is an ACAT inhibitor. Eflucimibe regulates endogenous hypercholesterolemia in a synergistic manner in New Zealand rabbits fed a casein-enriched diet. In vivo, orally administered Eflucimibe displayed high potency and efficacy as an antihypercholesterolemic compound in different cholesterol-fed animals (guinea-pig, rat, rabbit).
Eflucimibe is an ACAT inhibitor. Eflucimibe regulates endogenous hypercholesterolemia in a synergistic manner in New Zealand rabbits fed a casein-enriched diet. In vivo, orally administered Eflucimibe displayed high potency and efficacy as an antihypercholesterolemic compound in different cholesterol-fed animals (guinea-pig, rat, rabbit).
别名
L-0081, L0081, F-12511, F12511
化学信息
分子量
469.72
分子式
C29H43NO2S
CAS No.
191791-65-8
储存&溶解度
存储
Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
评论内容